PACIFIC phase III trial data at ESMO showed an estimated 35% of non-small cell lung cancer patients treated with Imfinzi had not progressed after four years.- AstraZeneca

Updated results from the PACIFIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed following concurrent chemoradiation therapy (CRT). One in three patients with NSCLC are diagnosed at Stage III, where the majority of tumours are unresectable (cannot be removed with surgery). Prior to the approval of Imfinzi in this setting, no new treatments beyond CRT had been available to these patients for decades. The results from the updated post-hoc analyses showed an estimated four-year overall survival rate of 49.6% for Imfinzi versus 36.3% for placebo after CRT. Median OS was 47.5 months for Imfinzi versus 29.1 for placebo. With a maximum treatment course of one year, an estimated 35.3% of patients treated with Imfinzi had not progressed four years after enrolment versus 19.5% for placebo. These data build on The New England Journal of Medicine publication from 2018 demonstrating a significant benefit for Imfinzi in the OS primary endpoint. Corinne Faivre-Finn, Professor at The University of Manchester and The Christie NHS Foundation Trust, and a lead investigator in the PACIFIC Phase III trial, said: “Previously, only 15 to 30 per cent of patients with unresectable, Stage III non-small cell lung cancer survived five years, and the majority eventually progressed to metastatic disease. These data show about half of patients treated with Imfinzi survived four years, and an estimated 35 per cent had not progressed, a remarkable advance in this curative-intent setting.”